Early intervention with ruxolitinib improves spleen response in patients with myelofibrosis
this post hoc analysis evaluated spleen response(defined as percentage of patients who achieved ≥50%reduction from baseline in palpable spleen length) andchange from baseline in spleen length at Weeks 12, 24,and 48. At Week 24, hrQoL was assessed by the percent-age of patients achieving Functional Assessment ofCancer therapy–Lymphoma (FACt-Lym) response(≥6.5-point increase from baseline in FACt-Lym totalscore, the lower limit of the minimum clinically importantdifference [7]) and change from baseline in FACt-Lymtotal score. time from first study dose to date of deathwas used to assess oS.
Authors
- Evan M. Braunstein (ORCID: https://orcid.org/0000-0001-5072-7636)
- Paola Guglielmelli (ORCID: https://orcid.org/0000-0003-1809-284X)
- Pankit J. Vachhani (ORCID: https://orcid.org/0000-0001-9779-6217)
- Haifa Kathrin Al‐Ali (ORCID: https://orcid.org/0000-0001-5009-2239)
- J.E. Hamer-Maansson
- Jennifer Repp
Institutions
- University of Alabama at Birmingham (US)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- University Hospital in Halle (DE)
- University of Florence (IT)
- Incyte (United States) (US)
Publication Details
- Journal
- Leukemia & lymphoma/Leukemia and lymphoma
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1080/10428194.2024.2447884
- Citations
- 1
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- Novartis Pharmaceuticals Corporation
- Incyte